Floatz logo

Alectinib

Hematopoietic And Lymphoid System Neoplasm

Cancer Research UKSmall moleculePhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

133 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Dexasone
City of Hope Medical Center
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Alectinib is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
66 / 100
View asset →
anaplastic large cell lymphomaActive
B
Indicative · Phase 2/3
63 / 100
View asset →
lung cancerActive
B
Indicative · Phase 4
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →